drugset / Trial / NCT04810104
Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug
Phase 2
Withdrawn
King's College London
AstraZeneca · collabHelse Stavanger HF · collabInnovative Medicines Initiative · collabMasaryk University · collabMichael J. Fox Foundation for Parkinson's Research · collabNorges Parkinsonforbund, Norway · collabParkinson's UK · collabStichting Lygature · collabUniversity of Exeter · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To test for the first time the potential of a nicotinic agonist on cognitive symptoms in people with mild cognitive impairment (MCI) in Parkinson's disease (PD), referred to as PD-MCI.
Timeline
- Start
- 2022-10
- Primary completion
- 2024-01
- Completion
- 2024-04
Outcome
Outcome not reported
Stopped: “Delays due to COVID”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AZD0328 | Small molecule | 0.5 mg | Oral |